Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry [2]. Core Insights - During the period from March 9 to March 15, 2026, a total of 98 innovative drugs/improved new drugs were submitted for clinical trials or market approval, with 82 domestic and 16 imported applications [8]. - A total of 86 innovative drugs/improved new drugs received "implied permission" for clinical trials, including 48 chemical drugs and 37 biological drugs [8]. - Notable drugs include SG-12 injection for chronic hepatitis B and SKB-575 injection for atopic dermatitis, both of which received clinical trial approval [9][10]. Summary by Sections 1. Domestic Innovative Drugs/Improved New Drugs - 1.1 Overview: 98 applications for clinical trials or market approval were recorded, with 82 domestic and 16 imported [8]. - 1.2 Clinical Trial Approvals: 86 drugs received implied permission for clinical trials, including significant drugs like SG-12 and SKB-575 [8][9]. - 1.3 Market Approvals: No new drugs were approved for market this week [29]. 2. Domestic Generic Drugs/Biosimilars - 2.1 Overview: 41 applications for generic drugs were submitted, with 36 for new registration and 4 for clinical trials [30]. - 2.2 Consistency Evaluation: 6 products passed consistency evaluation, with a total of 55 products deemed equivalent [31]. 3. Policy and Regulation - 3.1 Policy Overview: The report summarizes key policies affecting the pharmaceutical industry, including the implementation of the Drug Administration Law [3]. - 3.2 Detailed Policy Explanation: Specific regulations and their implications for the industry are discussed [3]. 4. Global Innovative Drug Development - 4.1 Global R&D Overview: The report highlights the progress of the top 10 innovative drugs globally, including significant approvals and clinical trial results [4]. - 4.2 Clinical Trial Outcomes: The report details both successful and failed clinical trials for various drugs, indicating the competitive landscape [4].

Core Viewpoint - The approval of Longpei Growth Hormone Injection (Skytrofa) by Weisheng Pharmaceutical marks a significant advancement in the long-acting growth hormone market, being the only product that outperforms daily formulations for treating pediatric growth hormone deficiency (PGHD) [1][5][6]. Product Differentiation - Longpei Growth Hormone utilizes a natural molecular structure identical to the amino acid sequence of human growth hormone, distinguishing it from other recombinant products [1]. - The product's unique pricing strategy focuses on the mid-to-high-end market, leveraging its differentiated advantages and aligning with the needs of families seeking effective treatment options for their children [3][19]. Clinical Efficacy - Clinical trial data indicates that Longpei Growth Hormone achieves an annualized growth rate of 10.66 cm after 52 weeks, significantly higher than the 9.75 cm achieved with traditional daily formulations [5][6]. - It is the only long-acting growth hormone approved by the National Medical Products Administration (NMPA) with a label stating it is superior to daily formulations, providing a strong basis for physician prescriptions and parental choices [6]. Safety and Convenience - Longpei Growth Hormone has demonstrated a safety profile comparable to daily formulations, with a low incidence of adverse events, primarily mild to moderate [7]. - The product requires only weekly injections, reducing the frequency of administration and enhancing the overall patient experience, while also being stable at room temperature for six months [7]. Value-Added Services - Weisheng Pharmaceutical is collaborating with high-end private medical institutions to provide comprehensive after-sales services, tracking patient progress and adjusting treatment plans as necessary [8]. Market Potential - Analysts predict that Longpei Growth Hormone could achieve sales exceeding 1 billion RMB by 2028, supported by successful overseas market performance and a robust domestic channel strategy [11][12]. - The company has established partnerships with key players in the industry to enhance market penetration and distribution efficiency, targeting different customer segments effectively [13][16][17]. Industry Dynamics - The growth hormone market is undergoing a transformation, with the entry of Longpei Growth Hormone filling a gap in the high-end segment and responding to the increasing demand for quality and safety in pediatric treatments [25][28]. - The overall market for growth hormones is expected to reach approximately 20 billion RMB by 2030, with long-acting formulations projected to capture a significant share due to their convenience and efficacy [19][27]. Investment Value - Weisheng Pharmaceutical's transition from a research-focused entity to a commercially viable company is seen as a pivotal moment for its valuation, with the successful launch of Longpei Growth Hormone serving as a catalyst for future growth [21][26]. - The company's diversified pipeline, including other innovative treatments, positions it well for sustained growth and market relevance [26].

Core Insights - The long-acting growth hormone market in China is experiencing rapid growth, with market share increasing from less than 10% in 2018 to over 35% in 2023, driven by demands for efficacy and treatment experience [1][2]. Product Breakthrough - The core product of Weisheng Pharmaceutical, Lonapegsomatropin, has received approval from the National Medical Products Administration, marking it as the first product in China with both long-acting and natural structure advantages, addressing unmet clinical needs [2][3]. - Lonapegsomatropin is the only long-acting growth hormone (LAGH) clinically proven to outperform daily growth hormone formulations, showcasing its Best-in-Class (BIC) attributes [3][4]. Clinical Validation - Weisheng has completed critical Phase III trials for Lonapegsomatropin in treating pediatric growth hormone deficiency (PGHD), demonstrating its efficacy and safety compared to daily injections [4][5]. - Multiple key Phase III trials globally support the product's use in initial treatment, conversion therapy, and long-term medication, providing solid evidence for its market introduction [5]. Commercialization Strategy - The approval of Lonapegsomatropin represents a pivotal moment for Weisheng, which has established a comprehensive commercialization system to facilitate product launch and market penetration [6][7]. - A strategic partnership with Anke Bio will enhance the promotion of Lonapegsomatropin in China, leveraging Anke's extensive experience and market presence in the growth hormone sector [7]. Market Potential - The global market for Lonapegsomatropin has already seen success, with sales in the U.S. projected to grow from €179 million in 2023 to €206 million by 2025, indicating strong market acceptance [8]. - In China, there is a significant supply-demand gap in PGHD treatment, with an estimated 3.4 million patients and a treatment rate of only 5.3%, suggesting substantial growth potential for long-acting growth hormones [8]. Pipeline and Future Growth - Weisheng's pipeline includes promising candidates for other endocrine disorders, reinforcing its long-term growth strategy and market presence [9]. - The commercialization of Lonapegsomatropin is expected to generate continuous cash flow and support the development of future products, marking a new phase of accelerated growth for the company [9]. Market Positioning - The Hong Kong innovative pharmaceutical sector is transitioning from a research-driven valuation to a profit realization phase, with Weisheng positioned as a rare entity with an approved long-acting growth hormone product [10]. - The competitive landscape for long-acting growth hormones in China is becoming clearer, with Lonapegsomatropin expected to steadily increase its market share over the next 3-5 years, positively impacting the company's valuation [10].

Core Insights - The long-acting growth hormone market in China has seen a significant increase, with its market share rising from less than 10% in 2018 to over 35% in 2023, driven by the dual demand for "treatment efficacy certainty" and "treatment experience" [1] - The approval of Weisheng Pharmaceutical's long-acting growth hormone, Lonapegsomatropin, marks a critical milestone for the company, positioning it as a potential "best-in-class" product in the market [2] - The product addresses key issues in pediatric growth hormone deficiency treatment, particularly the challenges of treatment adherence and efficacy stability, with a unique weekly dosing regimen [3][4] Product Breakthrough - Lonapegsomatropin is the first long-acting growth hormone in China that combines a weekly administration schedule with a natural hormone structure, providing a targeted solution to existing treatment challenges [3] - The product has demonstrated superior efficacy compared to daily injection formulations in clinical trials, establishing its best-in-class status [4] - The innovative TransCon prodrug technology allows for a safer and more effective release of growth hormone, reducing the incidence of adverse reactions [4] Commercialization Strategy - Weisheng Pharmaceutical has established a comprehensive commercialization framework to support the product's market entry, including partnerships to enhance distribution and reach [6][7] - The company has signed a strategic cooperation agreement with Anke Bio, leveraging its extensive experience and market presence to accelerate the promotion of Lonapegsomatropin [7] - The product has already achieved commercial validation in global markets, with significant sales growth projected in the coming years [7] Market Potential - There is a substantial unmet need in the pediatric growth hormone deficiency treatment market in China, with an estimated 3.4 million patients and a treatment rate of only 5.3% [8] - The long-acting growth hormone market is expected to capture approximately 80% of the overall growth hormone market by 2030, with Weisheng aiming for a 15%-20% market share [8] - The company’s pipeline includes additional promising products, enhancing its long-term growth prospects and market positioning [8] Industry Context - The Hong Kong innovative pharmaceutical sector is transitioning from a "research-driven valuation" to a "profit realization valuation" phase, with Weisheng's product launch aligning with this trend [10] - The competitive landscape for long-acting growth hormones in China is becoming clearer, with Lonapegsomatropin expected to steadily increase its market share over the next 3-5 years [10] - The successful commercialization of Lonapegsomatropin is anticipated to significantly enhance the company's valuation and performance, reflecting its industrial development capabilities [10]

Core Viewpoint - The recent prescription of Palopegteriparatide at a hospital in Hainan marks a significant milestone for the company in the endocrine innovation field, with the drug being the first and only parathyroid hormone replacement therapy globally [1][2]. Group 1: Company Developments - The stock of Viesheng Pharmaceutical (02561) rose by 4.68%, reaching HKD 39.8 [1]. - The CEO of Viesheng Pharmaceutical highlighted the importance of the first prescription of Palopegteriparatide as a step towards innovation in the endocrine sector [1]. - The company is committed to accelerating the domestic approval process for Palopegteriparatide and continuing its focus on innovative endocrine therapies [1]. Group 2: Product Pipeline - The company is advancing its long-acting growth hormone, Long-acting Growth Hormone, which is expected to be approved for domestic use in the second half of 2025, potentially becoming the third long-acting growth hormone in China [2]. - Viesheng Pharmaceutical has two unique products, namely Navepeptide and Palopegteriparatide, with the latter expected to submit a market application by the end of 2025 [2]. - Collaborations with WuXi Biologics and Anke Bio are in place to enhance local production and commercialize products, indicating a promising market outlook [2].

Group 1 - The core point of the news is that Viesheng Pharmaceutical-B (02561) has seen a stock increase of over 4%, attributed to the first prescription of Palopegteriparatide at a hospital in Hainan, marking a significant milestone for the company in the endocrine field [1] - Palopegteriparatide is the first and only parathyroid hormone replacement therapy approved in major markets in Europe and the US, indicating its potential to address traditional treatment challenges for patients [1] - The CEO of Viesheng Pharmaceutical emphasized the importance of this prescription as a step towards innovation in endocrine therapies and the company's commitment to accelerating the drug's approval process in China [1] Group 2 - The company is advancing its long-acting growth hormone, Longpei Growth Hormone, which is expected to be approved for domestic market launch in the second half of 2025, potentially becoming the third long-acting growth hormone in China [2] - Viesheng Pharmaceutical has two unique products, including Palopegteriparatide, which is anticipated to submit a market application by the end of 2025 [2] - Collaborations with WuXi Biologics and Anke Bio have been established to enhance local production and commercialization efforts, indicating a promising market outlook for the company's products [2]

Core Viewpoint - Vison Pharma-B (02561) has seen a significant stock price increase, currently trading at 44.68 HKD, reflecting a rise of 2.81% [1] Group 1: Company Developments - The fastest R&D progress for Vison Pharma is with Long-acting Growth Hormone, expected to be approved for domestic market launch in the second half of 2025, potentially becoming the third long-acting growth hormone available in China [1] - The company has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] - In June, Vison Pharma partnered with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, Vison Pharma collaborated with Anke Bio (300009) to jointly promote product commercialization, indicating promising future market prospects [1]

Core Viewpoint - Vison Pharma-B (02561) has seen a stock price increase of nearly 4%, currently trading at 44.68 HKD, driven by positive developments in its product pipeline and strategic partnerships [1] Group 1: Product Development - The fastest progressing product in Vison Pharma's pipeline is Long-Acting Growth Hormone, expected to receive domestic approval in the second half of 2025, potentially becoming the third long-acting growth hormone approved in China [1] - The company currently has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] Group 2: Strategic Partnerships - In June, Vison Pharma entered into a collaboration with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, the company partnered with Anke Bio to jointly promote the commercialization of its products, indicating a promising market outlook [1]

Core Insights - The Hong Kong pharmaceutical market has shown a structural trend since 2025, with the innovative drug sector becoming a focal point for investment due to its transition to profitability and international expansion [1][2] Industry Overview - In the first half of 2025, 149 Hong Kong-listed pharmaceutical companies reported a 29.7% year-on-year increase in net profit attributable to shareholders, with 36 innovative drug companies generating revenues of 28.5 billion yuan, marking a 15.8% growth [1] - The innovative drug sector has transitioned from a "research and development phase" to a "commercialization phase," driven by companies like BeiGene and Innovent Biologics, which have validated their commercialization capabilities [2] - The current market sentiment favors "high cost-performance" targets, with a focus on companies that have stable R&D pipelines and mature commercialization systems [2] Investment Opportunities - The innovative drug sector is characterized by "high certainty and high elasticity," with increased market rotation and investment interest in companies with strong performance and growth potential [2][3] - Companies with differentiated innovation capabilities and global commercialization potential are recommended for investment, as they are expected to experience rapid revenue growth and profitability [3] - The market is actively seeking investment targets that combine "valuation recovery and product realization," with a focus on companies like Vison Pharma, which is positioned in the growth hormone market [4][5] Company Spotlight: Vison Pharma - Vison Pharma is recognized as an undervalued innovative drug company with both valuation recovery and growth potential, focusing on the growth hormone market [5][6] - The company's core product, Lonapegsomatropin, is expected to be commercialized in China, with significant market potential and a strong clinical validation track record [6][7] - Vison Pharma has established strategic partnerships to enhance its commercialization capabilities, including exclusive promotion agreements and local production arrangements [7][8] Market Positioning - Vison Pharma's upcoming product launch is crucial for its value realization, with the potential to capture a significant market share in the long-acting growth hormone segment [6][9] - The company is well-positioned in a "value gap" state, avoiding the risks associated with early-stage biotech while not being assigned the high valuations typical of mature pharmaceutical companies [9]

Core Viewpoint - The stock price of Weisheng Pharmaceutical has been stagnant since its listing on the Hong Kong stock market, reflecting a typical scenario of valuation logic in the innovative drug industry and short-term market dynamics [1][3] Group 1: Market Dynamics - Weisheng Pharmaceutical's core product, Longpei growth hormone, is in the final stage of approval, with commercial potential yet to be realized, leading to a lack of patience from short-term investors [1] - The total trading volume since the IPO is approximately 700 million HKD, with a turnover rate of about 11%, indicating that new investors are currently inactive after the initial trading [1][2] - The upcoming expiration of the first lock-up period for new shares is creating a temporary stalemate between bullish and bearish forces in the market [3] Group 2: Clinical and Commercial Potential - Longpei growth hormone is the only long-acting growth hormone clinically proven to outperform daily formulations, with its approval process nearing completion, which is seen as a significant breakthrough [6][8] - The product has demonstrated substantial commercial potential in overseas markets, with sales reaching 202 million euros and capturing 45% of the long-acting segment in the U.S. market [8] - The Chinese market presents a favorable environment for Longpei growth hormone, with a projected market size of 21.1 billion CNY by 2030, where capturing just one-third of the market could yield sales of 7 billion CNY [9] Group 3: Valuation Logic - The valuation of innovative drug companies typically follows a dynamic assessment framework based on clinical stage progression and the scarcity of indications, with late-stage assets commanding a premium [11][12] - Weisheng Pharmaceutical's pipeline is at a critical value release point, with major institutions projecting target prices between 80-82 HKD, reflecting a rational expectation of the product's market entry [12][13] - The company’s other two core pipelines also hold significant value, with unique treatments for rare diseases that are expected to enhance the overall valuation [14] Group 4: Investment Outlook - The current divergence between short-term market sentiment and the company's intrinsic value presents an opportunity for value investors to identify certainty in the market [15] - As the year-end approaches, Weisheng Pharmaceutical is set to benefit from multiple positive factors, including product approval and capacity release, transitioning from a "story-driven" phase to one focused on "performance verification" [15]